1350456-56-2
Chemical Structure
Fmoc-Val-Cit-PAB-MMAE
- CAS No.: 1350456-56-2
- Formula:C73H104N10O14
- Molecular Weight:1345.67
IUPAC Name: 4-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
InChIKey: RHQGFVOXIOMBMC-UUMMFNFXSA-N
SMILES: O=C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@]([C@@H](C)CC)([H])[C@H](OC)CC(N(CCC2)[C@]2([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C3=CC=CC=C3)O)=O)=O)=O)=O)=O)C=C1)=O)=O)OCC4C5=CC=CC=C5C6=CC=CC=C46
Biological Activity: Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fmoc-Val-Cit-PAB-MMAE | 98.85% | Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Val-Cit-PAB-MMAE (GMP) | Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Phe-C4-VC-PAB-MMAE | 99.54% | Mal-Phe-C4-VC-PAB-MMAE is a drug-linker conjugate for ADC composed of MMAE conjugated to the Mal-Phe-C4-VC-PAB linker. Mal-Phe-C4-VC-PAB-MMAE can be used to synthesize ROR1-targeting antibody-drug conjugates (ADCs) for research on ROR1-expressing cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OH-Glu-Val-Cit-PAB-MMAE | 99.03% | OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-VAP-MMAE | Fmoc-VAP-MMAE is a agent-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE (HY-15162), with a protective Fmoc group. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Aminooxy)acetamide-Val-Cit-PAB-MMAE | 96.87% | (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VcMMAE (Standard) | 99.95% | VcMMAE (Standard) is the analytical standard of VcMMAE. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Boc-Val-Cit-PAB-MMAE | 99.72% | Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC, which is composed of a linker Boc-Val-Cit-PAB (HY141141) and a Microtubule inhibitor MMAE (HY-15162). Boc-Val-Cit-PAB-MMAE can be used for ADC synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aminocaproyl-Val-Cit-PABC-MMAE | 99.89% | Aminocaproyl-Val-Cit-PABC-MMAE is an Drug-linker conjugate for ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-Val-Cit-PAB-MMAF-OtBu | Fmoc-Val-Cit-PAB-MMAF-OtBu is a conjugate of MMAF and ADC linker, which can be coupled with the corresponding antibody to form an ADC molecule to exert anti-tumor activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DBCO-Val-Cit-PAB-MMAE | 95.90% | DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
